Pneumonia remains an important medical and social problem today, even despite significant progress in diagnostic methods, treatment approaches, etc. This is also due to the prevalence of this pathology among the population of different age groups, high mortality rates, and economic costs for treatment.

The aim of the work was to find out the role of TNP-alpha, interleukin-6, interleukin-10 for the pathogenesis of experimental pneumonia.

Methods. Experimental studies of the definition of FNP-alpha, interleukin-6, interleukin-10 were performed in serum guinea pigs (males) with experimental pneumonia for 7, 14, 21 days of the experiment. The experimental pneumonia model was reproduced according to the method M. S. Regeda. The contents of these cytokines were determined by solid-phase immunoassay (ELISA). In doing so, a set of reagents for quantitative immunoassay analysis of correspondent cytokine production «Diacalone» (France) was used. Statistical processing of the obtained data was carried out using the Student method.

Results. Experimental studies have shown the role of cytokines, namely TNF-alpha, interleukin-6 6 (IL-6) and interleukin-10 (IL-10), in the formation of the pathogenesis of experimental pneumonia and revealed a significant increase in the content of proinflammatory interleukins, TNF-alpha and IL-6 in the blood serum of guinea pigs on days 7, 14 and 21 of the experiment compared to the control group. The content of IL-10, which exhibits anti-inflammatory activity, decreased on all days of the experiment compared to intact animals.

Conclusions. The results presented in the article may indicate that the progression of destructive metabolic changes in the lungs of guinea pigs activates the immunoinflammatory response.

Ключові слова: pathogenesis, experimental pneumonia, interleukins, inflammatory process

Повний текст: PDF (Ukr)

1. Frolova T. V., Borodina O. S., Tereschenkova I. I., Stenkova N. F., Sinyaeva I. R. Community-acquired uncomplicated pneumonia in children with different physical development. Охорона здоров'я дітей та підлітків. 2019; 1: 88-91.
2. O. S. Borodina Community-acquired uncomplicated pneumonia of children: interaction with cytokin response and physical development. Досягнення біології та медицини. 2018; 2:25-28.
3. Сміян О. І., Горбась В. А. Негоспітальна пневмонія у дітей шкільного віку: вплив на імунну систему організму : монографія. Суми : Сумський державний університет, 2024. 111 с.
4. Bereznyakov V.I. The state of cellular and humoral parts of the immune system in community-acquired pneumonia. Україна. Здоров'я нації. 2022; 1: 107-110.doi.org/10.24144/2077-6594.1.1.2022.254649
5. Eshwara VK, Mukhopadhyay C, Rello J. Community-acquired bacterial pneumonia in adults: An update. Indian J Med Res. 2020; 151 (4): 287-302.doi.org/10.4103/ijmr.IJMR_1678_19
6. Lanks CW, Musani AI, Hsia DW. Community-acquired Pneumonia and Hospital-acquired Pneumonia. Med Clin North Am. 2019; 103 (3): 487-501.doi.org/10.1016/j.mcna.2018.12.008
7. Huang Y, Liu A, Liang L, et al. Diagnostic value of blood parameters for community-acquired pneumonia. Int Immunopharmacol. 2018; 64: 10-15.doi.org/10.1016/j.intimp.2018.08.022
8. Brands X, Haak BW, Klarenbeek AM, Otto NA, Faber DR, Lutter R, Scicluna BP, Wiersinga WJ, van der Poll T. Concurrent Immune Suppression and Hyperinflammation in Patients With Community-Acquired Pneumonia. Front Immunol. 2020 May 6;11:796.doi.org/10.3389/fimmu.2020.00796
9. M. S. Regeda, L. A. Furdychko, M. M. Regeda-Furdychko, S. M. Regeda Features of changes of processes of lipid peroxidation the antioxidant system in the lungs in the early period of the formation of experimental pneumonia. Achievements of Clinical and Experimental Medicine. 2016;1:41-43.
10. A. V. Demchuk. Community-acquired pneumonia clinical course peculiarities in patients with cardio-vascular diseases. Український пульмонологічний журнал.2015;4:22-26.
11. Козар М. Pneumococcal infection in children and adults in the position of a specialist. SworldJournal. 2023; 2(22-02): 90-94.doi.org/10.30888/2663-5712.2023-22-02-052
12. Регеда МС. Експериментальні моделі алергійного альвеоліту та пневмонії. Методичні вказівки: Львів. 2024. 10 с.